Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.

Kimura S, Harada T, Ijichi K, Tanaka K, Liu R, Shibahara D, Kawano Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Lung Cancer.2018 Jun; 120:98-107.

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I.

J Thorac Oncol. 2018 Mar 27.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Apr;118:36-40. 

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Iwama E, Nakanishi Y, Okamoto I.

Expert Rev Anticancer Ther. 2018 Jan 27:1-10. 

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Nov;113:72-78.

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.

Yabuuchi H, Kawanami S, Iwama E, Okamoto I, Kamitani T, Sagiyama K, Yamasaki Y, Honda H.

Radiology. 2018 Feb;286(2):685-695.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR

Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I.

mutations. Oncotarget. 2017 Jul 12. doi: 10.18632/oncotarget.19243.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Ogata H, Yamamoto Y, Harada T, Nakanishi Y, Okamoto I, Iwama E, Kato K, Oda Y.

J Thorac Oncol. 2017 May;12(5): e46-e47.

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Ogata H, Okamoto I, Yoshimoto G, Obara T, Ijichi K, Iwama E, Harada T, Akashi K, Nakanishi Y.

Respir Investig. 2017 Mar;55(2):181-183. 

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.

Hidaka N, Iwama E (Corresponding author), Kubo N, Harada T, Miyawaki K,　 Tanaka K, Okamoto I, Baba E, Akashi K, Sasaki H, Nakanishi Y.

Lung Cancer 108 (2017), 75-82.

Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401).

Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.

J Thorac Oncol. 2017 Jul;12(7):1161-1166.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.

Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Ann Oncol. 2017 Jan 1;28(1):136-141.

Development and Future Prospects of the Third-Generation EGFR-Tyrosine Kinase Inhibitor.

Sakata S, Iwama E, Okamoto I.:

Gan To Kagaku Ryoho. 2015 Aug; 42(8):935-9

Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.:

Invest New Drugs. Oct;33(5):1148-50. 

Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.

Ikesue H, Watanabe H, Hirano M, Chikamori A, Suetsugu K, Ryokai Y, Egashira N, Yamada T, Ikeda M, Iwama E, Harada T, Takayama K, Nakanishi Y, Masuda S.:

Biol Pharm Bull. 2015;38(8):1192-8.

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.:

Clin Cancer Res. 2015 Sep 1;21(17):4014-21.

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR.

Iwama E, Takayama K, Harada T, Okamoto I, Ookubo F, Kishimoto J, Baba E, Oda Y, Nakanishi Y.: 

Oncotarget. 2015 Aug 21;6(24):20466-73

Successful treatment with alectinib after crizotinib-induced esophageal ulceration.

Yoneshima Y, Okamoto I, Takano T, Enokizu A, Iwama E, Harada T, Takayama K, Nakanishi Y.:

Lung Cancer. 2015 Jun;88(3):349-51.

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

Fujii A, Harada T, Iwama E, Ota K, Furuyama K, Ijichi K, Okamoto T, Okamoto I, Takayama K, Nakanishi Y.:

Cancer Genet. 2015 May;208(5):271-8.

Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.

Li H, Wang S, Takayama K, Harada T, Okamoto I, Iwama E, Fujii A, Ota K, Hidaka N, Kawano Y, Nakanishi Y.:

Lung Cancer. 2015 Apr;88(1):1-8.

PICT1 expression is a poor prognostic factor in non-small cell lung cancer.

Okamura K, Takayama K, Kawahara K, Harada T, Nishio M, Otsubo K, Ijichi K, Kohno M, Iwama E, Fujii A, Ota K, Koga T, Okamoto T, Suzuki A, Nakanishi Y.: 

Oncoscience. 2014 May 25;1(5):375-82.

Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.

Yoneshima Y, Okamoto I, Arimura-Omori M, Kimura S, Hidaka-Fujimoto N,Iwama E, Harada T, Takayama K, Nakanishi Y. Invest New Drugs. 2015 Apr;33(2):510-2.

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.

Li H,Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y. Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Azuma K, Ota K, Kawahara A, Hattori S,Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Ann Oncol. 2014 Oct;25(10):1935-40.

Personalized medicine in non-small-cell carcinoma.

Iwama E, Takayama K, Baba E, Nakanishi Y.

Fukuoka Igaku Zasshi. 2014 Mar;105(3):57-66.

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. 

Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y.

Onco Targets Ther. 2014 Mar 5; 7: 375-385.

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases. 

Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S,  Oda H,  Esaki T, Takayoshi K,  Uchino K,  Tamura S,  Kumagai H,  Iwama E,  Shirakawa T,  Mitsugi K,  Takaishi S,  Akashi K,  Baba E. 

Anticancer Res. 2014 Jan; 34(1): 215-20.

Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.

Furuyama K, Harada T,Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y. Cancer Sci. 2013 May;104(5):584-9. 

Cancer-related PRUNE2 protein is associated with nucleotides and is highly expressed in mature nerve tissues.

Iwama E, Tsuchimoto D, Iyama T, Sakumi K, Nakagawara A, Takayama K, Nakanishi Y, Nakabeppu Y.  J Mol Neurosci. 2011 Jun; 44(2): 103-14.